Bass Jr., J.B., Farer, L.S., Hopewell, P.C., O’Brien, R., Jacobs, R.F., Ruben, F., Snider Jr, D.E. and Thornton, G. (1994) Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children. American Thoracic Society and the Centers for Disease Control and Prevention. American Journal of Respiratory and Critical Care Medicine, 149, 1359-1374.
https://doi.org/10.1164/ajrccm.149.5.8173779

has been cited by the following article:

• TITLE: Identification, Synthesis, Isolation and Spectral Characterization of Multidrug-Resistant Tuberculosis (MDR-TB) Related Substances

  AUTHORS: Sureshbabu Jayachandra, Madhuresh Kumar Sethi, Vipin Kumar Kaushik, Vijayakrishna Ravi, Saiprasad Kottolla, Vikas Chandra Dev, Purbita Chakraborty

  KEYWORDS: Asymmetric Synthesis, Tuberculosis (TB), Human Immunodeficiency Virus (HIV), Mycobacterium tuberculosis, Mycobacterium africanus, Mycobacterium bovis, Directly Observed Treatment Short (DOTS), High Prevalence of Multi-Drug-Resistant (MDR) and Extensively Drug Resistant (XDR)

  JOURNAL NAME: Green and Sustainable Chemistry, Vol.8 No.2, May 31, 2018

  ABSTRACT: Several related substances were detected at trace level in (2R)-2,3-dihydro-2-methyl-6-nitro-2-[[4-[4-[4-(trifluoromethoxy)phenoxy]-1-piperidinyl] phenoxy] methyl]imidazo[2, 1-b]oxazole drug substance by a newly developed high-performance liquid chromatography method. All related substances were characterized rapidly but some impurities were found to be intermediates. Proposed structures were further confirmed by characterization using NMR, FT-IR, and HRMS techniques. Based on the spectroscopic data; unknown related sub-stances were characterized as 1-(Methylsulfonyl)-4-[4-(trifluoromethoxy) phenoxy]piperidine; 4-{4-[4-(Tri-fluoromethoxy)-phenoxy]piperidin-1-yl}phenol and 4-{4-[4-(trifluoromethoxy)phenoxy]piperidin-1-yl}phenyl methane sulfonate; 4-Bromophenyl methane sulfonate, Ethyl 3,6-dihydro-1(2H)-pyridine carboxylate, (2S)-3-(4-Bromophenoxy)-2-hydroxy-2-methylpropyl methane sulfonate, (2S)-3-(4-Bromophenoxy)-2-methylpropane-1,2-diyldimethane-sulfonate, (2S)-2-Methyl-3-(4-{4-[4-(trifluoromethoxy) phenoxy]-piperidin-1-yl} phenoxy)-propane-1,2-diyldimethane sulfonate, (S)-3-(4-Bromophenoxy)-2-methyl-propane-1,2-diol and corresponding Enantiomer, (2R)-2-[(4-Bromo-phenoxy)methyl]-2-methyloxirane and (2R)-2-[(4-bromophenoxy)methyl]-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazole. A possible mechanism for the formation of these related substances is also proposed.